zenocutuzumab-zbco

{
  "id": "MLC-T-ONC-017660",
  "term": "zenocutuzumab-zbco",
  "field": "Oncology and biomedicine",
  "definition": "A full-length IgG1 bispecific antibody with enhanced antibody-dependent cellular cytotoxicity (ADCC) directed against human epidermal growth factor receptor 2 (HER2; EGFR2, ERBB2) and human epidermal growth factor receptor 3 (HER3; ErbB3), with potential antineoplastic activity. Upon intravenous administration of zenocutuzumab, the bispecific antibody docks on HER2, and subsequently blocks heregulin-stimulated proliferation of tumor cells by binding HER3. In addition to inhibiting HER3-dependent signaling, simultaneous targeting of HER2 and HER3 by zenocutuzumab-zbco may overcome a common resistance mechanism driven by heregulin-mediated dimerization of HER2 and HER3. Zenocutuzumab-zbco is expected to eliminate tumor cells by recruiting natural killer (NK) cells to tumor cells coated with the bispecific antibody.",
  "synonyms": [
    "zenocutuzumab",
    "anti-HER2/Anti-HER3 bispecific monoclonal antibody MCLA-128",
    "anti-HER2 x Anti-HER3 bispecific monoclonal antibody MCLA-128"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/zenocutuzumab-zbco/"
}